SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Synthetic Blood (SYBD)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lance who wrote (225)8/11/1998 12:08:00 PM
From: t.gawarecki  Read Replies (1) of 307
 
MORE NEWS

Synthetic Blood International Announces Manager Appointment to NASA Research Project

Business Wire - August 10, 1998 09:15

KETTERING, OHIO--(BUSINESS WIRE)--Aug. 10, 1998--Synthetic Blood International, Inc. (SYBD) announced today that Elmo Blubaugh, Ph.D., manager of biosensor research, was selected to participate in a NASA evaluation of their advanced technology development biosensor research project.

The biosensor project, which is funded by NASA's life sciences division, is developing a number of physiological and biochemical sensors for use in field and space operations. Dr. Blubaugh served as group leader of the panel that evaluated technical aspects of the program. The recently completed evaluation, which included review of reports and a site visit to NASA's Ames Research Center at Moffat Field in California, was limited to a small, select group of scientists and research managers.

Dr. Blubaugh holds a Ph.D. in analytical chemistry and is an expert in chemical modification of electrode surfaces with thin polymer and metal films. He has been associated with SYBD since 1994 and has played a key role in the Company's development of an implanted glucose biosensor that is being developed to continuously monitor blood glucose levels in diabetics

"It is gratifying for Dr. Blubaugh to be recognized for his expertise and contributions to biosensor technology," said Robert Nicora, president. "It is also evidence that Synthetic Blood International is at the forefront of biosensor research and development."

In addition to developing the glucose biosensor, SYBD is developing Oxycyte(tm), a fluorocarbon-based blood substitute, and Fluorovent(tm), a perfluorocarbon liquid ventilation product.

SYBD is located in Kettering, Ohio and has a West Coast office in Irvine, California. The company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD. The Company has an Internet web site at www.sybd.com and an e-mail address of sybd@siscom.net.

CONTACT: Synthetic Blood International, Inc.
Joan Mahan, 800/809-6054
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext